Point Therapeutics Announces Resignation of William Whelan from Board of Directors.BOSTON -- Point Therapeutics, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : POTP POTP Point Therapeutics (stock symbol) POTP Part Of The Problem (World of Warcraft guild) ) today announced that because of his other commitments and responsibilities, William J. Whelan, Jr. has resigned from the Company's Board of Directors. Mr. Whelan has served on the Board since 1997. "We are very grateful for Bill's contributions, advice, and counsel in his 10 years of service to Point, and I am joined by the other directors in wishing him very well," said Don Kiepert, President, Chairman, and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Point Therapeutics. About Point Therapeutics, Inc.: Point is a Boston-based biopharmaceutical company which is currently studying its lead product candidate, talabostat, in two Phase 3 double blind placebo-controlled trials in non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia chronic lymphocytic leukemia n. Abbr. CLL Lymphocytic leukemia occurring mainly in older adults, characterized by slow onset and gradual progression of symptoms. . |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion